Molecules 2017, 22, 87
7 of 9
4.4. UPLC Analysis
Biotransformation mixtures were analyzed with a UPLC system (Acquity UPLC H-Class, Waters,
Milford, MA, USA) equipped with an analytic C18 reversed-phase column (Acquity UPLC BEH C18,
1.7
µ
m, 2.1 mm i.d.
×
100 mm, Waters). The operation conditions included a gradient elution using
water (A) containing 1% (v/v) acetic acid and methanol (B) with a linear gradient for nine min with
35% to 80% B and for another one minute with 80% to 85% B at a flow rate of 0.3 mL/min, injection
volume of 0.2 µL, and detection of the absorbance at 260 nm.
4.5. Purification and Identification of Biotransformation Products
The final reaction mixture obtained from the above biotransformation (in 100 mL of 50% methanol)
was centrifuged at 10,000 rpm and filtered with a 0.22
Then, the filtrate was injected into a preparative YoungLin HPLC system (YL9100, YL Instrument,
Gyeonggi-do, Korea) equipped with a preparative C18 reversed-phase column (Inertsil, 10 m,
20.0 mm i.d. 250 mm, ODS 3, GL Sciences, Eindhoven, The Netherlands) for purification of
µm nylon membrane under vacuum.
µ
×
the biotransformation products. The operational conditions for the preparative HPLC analysis were
the same as those in the UPLC analysis. The elution corresponding to the peak of the metabolite in
the UPLC analysis was collected, condensed under a vacuum, and then crystallized by freeze drying.
Finally, 27.9 mg of compound (1) and 33.3 mg of compound (2) were obtained. The structures of
the compounds were confirmed with NMR and mass spectral analysis. The mass spectral analysis
was performed on a Finnigan LCQ Duo mass spectrometer (ThermoQuest Corp., San Jose, CA, USA)
equipped with electrospray ionization (ESI). 1H- and 13C-NMR, HMQC, HMBC, COSY, and NOESY
spectra were recorded on an AV-700 NMR spectrometer (Bruker Corp., Billerica, MA, USA) at ambient
temperature. Standard pulse sequences and parameters were used for the NMR experiments, and all
chemical shifts were reported in parts per million (ppm, δ).
5,7,40-Trihydroxy-30-methoxyisoflavone ( ). 1H-NMR (DMSO-d6)
1 δ: 8.34 (1H, s, H-2), 7.13 (1H, d,
J = 2.1 Hz, H-20), 6.98 (1H, d, J = 8.1, 2.1 Hz, H-60), 6.82 (1H, d, J = 8.1, H-50), 6.37 (1H, d, J = 2.2 Hz,
H-8), 6.21 (1H, J = 2.2 Hz, H-6), 3.79 (3H, s, MeO-30); 13C-NMR (DMSO-d6): 180.1 (C-4), 164.8 (C-7),
162.0 (C-5), 157.6 (C-9), 154.1 (C-2), 147.3 (C-30), 146.7 (C-40), 122.3 (C-3), 121.7 (overlap, C-10, C-60),
115.3 (C-50), 113.3 (C-20), 104.3 (C-10), 99.1 (C-6), 93.8 (C-8), 55.7 (OCH3).
0
0
1
5,7,3 -Trihydroxy-4 -methoxyisoflavone (
2). H-NMR (DMSO-d6) δ: 8.28 (1H, s, H-2), 7.02 (1H, d, J = 2.1 Hz,
H-20), 6.96 (1H, d, J = 8.3, H-50), 6.93 (1H, dd, J = 8.3, 2.1 Hz, H-60), 6.32 (1H, d, J = 2.1 Hz, H-8),
6.17 (1H, d, J = 2.1 Hz, H-6), 3.79 (3H, s, MeO-40); 13C-NMR (DMSO-d6)
δ: 179.9 (C-4), 165.8 (C-7),
162.0 (C-9), 157.7 (C-2), 154.0 (C-40), 146.1 (C-30), 123.5 (C-10), 122.0 (C-3), 119.8 (C-60), 116.4 (C-20),
112.0 (C-50), 103.9 (C-10), 99.4 (C-6), 93.9 (C-8), 55.7 (OCH3).
4.6. Determination of Cell Viability
Cell viability was determined as previously reported [8] and described briefly below.
Dulbecco’s modified Eagle’s medium (DMEM) containing 10% (v/v) fetal bovine serum was used
◦
to cultivate the tested cells, which were incubated at 37 C in a humidified, CO2-controlled (5%)
incubator. After one day of incubation, the cells were treated with tested drugs for another two days.
The drug-treated cells were then harvested and the cell viability was measured according to our
5. Conclusions
0
0
The present study first developed a bio-production process for 5,7,4 -trihydroxy-3 -methoxyisoflavone
(1 2), where genistein was firstly biotransformed to
) and 5,7,30-trihydroxy-40-methoxyisoflavone (
30-hydroxygenistein by recombinant E. coli that expressed B. megaterium tyrosinase and the
produced 30-hydroxygenistein was then biotransformed to 5,7,40-trihydroxy-30-methoxyisoflavone